China's first listing of multidrug-resistant tuberculosis drugs

The State Food and Drug Administration has recently approved the implementation of Sri Lanka? (Betaquinoline fumarate tablets) is used as part of a combination therapy for the treatment of multidrug-resistant tuberculosis in adults (≥18 years). This is the first time in China to treat new multidrug-resistant tuberculosis drugs.

MDR-TB is a form of tuberculosis that is resistant to two of the most effective drugs in the first-line treatment of tuberculosis, isoniazid and rifampicin. The treatment options for patients with MDR-TB are more limited. Tuberculosis, especially MDR-TB, is one of the most significant public health problems in the world today. According to the World Health Organization, the number of new tuberculosis patients in China is as high as 1 million per year, including 70,000 patients with multidrug-resistant tuberculosis. Most of the drugs currently used for the treatment of tuberculosis have been approved before the 1960s, and the treatment options for MDR-TB are more limited.

Professor Nai Naihui, director of the tuberculosis department at Beijing Chest Hospital , said that MDR-TB was caused by a patient infected with a drug-resistant strain of Mycobacterium tuberculosis or due to a previously failed treatment plan. The number of new multidrug-resistant tuberculosis patients in China accounts for about 15% of the world each year. Bedaquinoline has an innovative mechanism of action that will bring good news to patients with multidrug-resistant tuberculosis in China.

In 2012, the US Food and Drug Administration accelerated the approval of beta-quinoline, and the EU also conditionally approved the drug. Through the Russian Federation and the partner of the CIS countries JSC Pharmstandard, the fumaric acid fumarate tablets were successfully registered in the Russian Federation. In addition, the fumarate tablets of fumaric acid have been approved in Armenia, Hong Kong Special Administrative Region of China, India, New Zealand, Peru, the Philippines, South Africa, South Korea, Taiwan, Turkmenistan and Uzbekistan.

The rational use of bedaquinoline is essential for the fight against multidrug-resistant tuberculosis. Xi'an Yangsen is working with partners and frontline medical workers in the field of tuberculosis prevention to establish a comprehensive drug management and use mechanism to ensure that Chinese patients can correctly and reasonably use betaacrine and reduce new drug-resistant tuberculosis. The possibility of emergence. Dr. Avery Ince, Vice President of Medical Affairs of Xi'an Janssen Pharmaceutical Co., Ltd. said: "With the cooperation of colleagues from all walks of life, we are confident that we can ensure the reasonable application of Betaquina in China."